Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01956279 · ClinicalTrials.gov registry record · Phase 2
Complementary Neurosteroid Intervention in Gulf War Illnesses (GWVI)
A Phase 2 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 170
- Enrollment target
NCT01956279: Completed Phase 2 study, sponsored by VA Office of Research and Development.
NCT01956279 is a Phase 2 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 170 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01956279, a Phase 2 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 170 participants
- Enrollment target
Study Summary
This study will investigate the use of adjunctive pregnenolone for the following: 1. fatigue that has limited usual activity, 2. musculoskeletal pain involving 2 or more regions of the body and, 3. cognitive symptoms (memory, concentration, or attentional difficulties by self-report) in Veterans deployed to the Gulf War theatre of operations between 1990 and 1991.
Interventions
- DRUG Placebo
- DRUG Pregnenolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2013-10-01 |
| Est. Completion | 2018-10-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01956279
The ClinicalTrials.gov registry entry for NCT01956279 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01956279 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01956279 about?
NCT01956279 is a clinical study titled "Complementary Neurosteroid Intervention in Gulf War Illnesses (GWVI)". This study will investigate the use of adjunctive pregnenolone for the following: 1. fatigue that has limited usual activity, 2. musculoskeletal pain involving 2 or more regions of the body and, 3. cognitive symptoms (memory, concentration, or attentional difficulties by self-report) in Veterans de...
What is the current status of trial NCT01956279?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2013-10-01. Estimated completion is 2018-10-10.
What interventions are being tested in trial NCT01956279?
The interventions under investigation include: Placebo (DRUG), Pregnenolone (DRUG).
Who is sponsoring clinical trial NCT01956279?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.